19 November 2015

Bayer Indonesia Encourages the Public to be aware of Hypogonadism and its Risks towards Men’s Health

  • PT Bayer Indonesia encourages public to be aware of the cause, effects and treatment towards hypogonadism.
  • Men with erectile dysfunction3,4 and type 2 diabetes mellitus2,5 are susceptible to hypogonadism. A testosterone replacement is recommended as a treatment for hypogonadism.
  • BAYER is a pharmaceutical company which provides full-fledged products for men’s health.

Jakarta, 19 November 2015 - PT Bayer Indonesia, a leading global pharmaceutical company, held a media dialogue with the theme SMILe (Seputar Masalah Intim Lelaki) in Jakarta today, with the aims to share knowledge on hypogonadism or testosterone deficiency syndrome which could affect men’s health and ultimately their quality of life.

 

Hypogonadism is a clinical symptom in which a man suffers of a lack of testosterone due to the testicle’s inability to produce physiological testosterone. A man may suffer this condition at any stage of his life; from the day he was born to the later days of his life. However, many men may not be aware they are suffering from this condition due to the lack of information regarding men’s health.

 

Hypogonadism is strongly associated with various symptoms causing morbidity1. A research conducted in the UK revealed there are approximately 414,000 men who suffer from erectile dysfunction (ED) 3,4 to date and 462,000 men suffers from type 2 diabetes2,5, among them may also be suffering from testosterone deficiency (TDS) and less than 5% of men are diagnosed with TDS.

 

dr. Nugroho Setiawan, MS,SpAnd stated: “Most of men are neglecting the symptom like a decrease in libido, erectile dysfunction, ease of exhaustion and perspiration and an increase in waist size. This condition is often perceived as normal which comes about with age. On top of that, hypogonadism can disrupt a man’s metabolism. According to a research, a man who lacks the testosterone hormone will also likely to suffer from metabolic syndromes such as diabetes mellitus, dyslipidemia; or vice versa, if a man suffers metabolic syndrome disease then there is a high possibility for him to suffer from hypogonadism, and ultimately culminated to a decline in the quality of life. Hypogonadism will cause disorderly impacts both psychologically and sexual dysfunction, i.e. reduce sexual desire and erectile dysfunction.”

 

According to Tara de Thouars, BA, M.Psi: “Testosterone is important to enable a man to have erections and experience sexual desire (libido). A men who suffer hypogonadism, probably will also suffer erectile dysfunctions, then he will face psychologically disorders i.e. depression, anxiety, and stress, which eventually led to problems with her partner. Therefore, it is important for men to discuss with his partner and willing to consult with doctor as well as psychologist, therefore he will get the right treatment.”

 

dr.Nugroho Setiawan, MS,SpAnd added: “Do not be shy to consult with doctor if you suffer of symptoms of hypogonadism like a decrease in libido erectile dysfunction. Hypogonadism or testosterone deficiency can be medicated with testosterone undecanoat. In case of erectile dysfunction (ED), Verdenafil can be used as additional therapy. Both drugs work synergistically to address men's health and certainly have been proven to help many men to achieve a better quality of life. Do not take a shortcuts treatment, such as consuming sexual tonics while suffering from hypogonadism and its symptoms, such as erectile dysfunction. We should indicate the root of the problem for right treatment therefore the quality of life can be improved.”

 

Reference:

1. Maggi M et al. J Sex Med 2007; 4:1056–1069. 2. Kapoor D et al. Diabetes Care 2007; 30:911–917. 3. Sexual Dysfunction Association http:// www.sda.uk.net/downloads/Impotence_or_erectile_dysfunction.pdf 4. Bodie J et al. J Urol 2003; 169:2262–2264. 5. Diabetes UK, personal communication. 27/02/09.

 

About Bayer: Science For A Better Life

 

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

 

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 20,0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com

Media Contact:

Anton Susanto
Head of Corporate Communication PT Bayer Indonesia
Phone: +62-21-30491506
E-mail: anton.susanto@bayer.com
www.bayer.co.id dan www.bayer.com

 

Forward-LookingStatements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.